Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer

Completed · Phase 1

Conditions studied: Breast Cancer

In brief

RATIONALE: Monoclonal antibodies such as HuHMFG1 can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of monoclonal antibody HuHMFG1 in treating women with locally advanced or metastatic breast cancer.

Key facts

Study ID

NCT00096057

Run by

Jonsson Comprehensive Cancer Center

People needed

24

Starts

2004-05-01

Expected to finish

2007-12-01

Last updated by the study team

2013-06-26

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center at UCLA — Los Angeles, California, United States
• University of Colorado Cancer Center at UC Health Sciences Center — Aurora, Colorado, United States
• M.D. Anderson Cancer Center at University of Texas — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.